School of Medicine
Showing 121-140 of 512 Results
-
Birgitt Schuele
Associate Professor (Research) of Pathology
BioBirgitt Schüle, MD, is an Associate Professor in the Department of Pathology at Stanford University School of Medicine. Her research focuses on medical genetics and stem cell modeling to uncover disease mechanisms and pathways involved in neurodegeneration in Parkinson's disease and related disorders. She is dedicated to developing novel therapeutic strategies that contribute to the advancement of precision medicine.
Dr. Schüle obtained her medical training from the Georg-August University Göttingen and Medical University Lübeck, Germany, between 1993 and 2001. She earned her doctoral degree in medicine (Dr. med.) in neurophysiology from the Georg-August University Göttingen in 2001. During her neurology internship from 2001 to 2002 at the Medical University of Lübeck under the guidance of Prof. Christine Klein. Subsequently, she pursued a postdoctoral fellowship in human genetics with Prof. Uta Francke at Stanford University School of Medicine from 2003 to 2005.
From 2005 to 2019, Dr. Schüle demonstrated leadership in spearheading critical clinical research programs and establishing essential biospecimen repositories for neurogenetics, translational stem cell research, and brain donation at the Parkinson's Institute and Clinical Center.
Currently, Dr. Schüle serves as the Associate Core Leader, Neuropathology, within the Stanford Alzheimer Research Center (ADRC). Her contributions to ADRC include genetic characterization, biobanking, and the establishment of a human induced pluripotent stem cell and post-mortem leptomeninges tissue bank. These resources are shared with the data and tissue repositories at the National Institutes of Health (NIH), facilitating collaborative research and advancing our understanding of neurodegenerative diseases.
Dr. Schüle's expertise and dedication in the field of neurodegeneration contribute significantly to the advancement of medical knowledge. She is recognized as a respected member of the scientific community, playing an important role in the pursuit of effective treatments and precision medicine approaches. -
Kevin Schulman
Professor of Medicine (Hospital Medicine), by courtesy, of Health Policy and of Operations, Information and Technology at the Graduate School of Business
BioDr. Schulman is a Professor of Medicine, Clinical Excellence Research Center (CERC) at the Stanford University School of Medicine, and, by courtesy, Professor of Operations, Information and Technology at Stanford’s Graduate School of Business. He is the Faculty Director of Stanford’s new applied master's degree program, the Master of Science in Clinical Informatics Management program.
Dr. Schulman is a health economist/health services researcher working at the intersection of business, medicine and technology. With over 500 publications, he has had a broad impact on several areas of health policy (Scopus h-index=81). His research has appeared in the New England Journal of Medicine, the Journal of the American Medical Association, and Health Affairs. He is the editor-in-chief of Health Management, Policy and Innovation (www.HMPI.Org), and Senior Associate Editor of Health Service Research (HSR).
He is a graduate of Dartmouth College, the New York University School of Medicine, and The Wharton Health Care Management Program. -
Liora Schultz
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
BioI am currently postdoctoral research fellow pursuing immunotherapy research in the oncology department at Stanford University. My clinical training as a pediatric hematology oncology fellow at Memorial Sloan Kettering Cancer Center highlighted the desperate need for novel therapeutic options for a subtype of aggressive pediatric leukemia, Acute Myeloid Leukemia (AML). Despite our best standard of care for AML, long term survival rates range from 50-60% with an unacceptably high relapse rate of 40%. The urgent need for novel treatments inspired me to pursue a research project in adoptive immunotherapy, genetically modifying Tcells to express artificial T cell receptors, termed chimeric antigen receptors (CARs), that target AML specific antigens. In parallel to my clinical training, I constructed an AML specific CAR and demonstrated its ability to redirect T cell function mediating eradication of AML cells. As the field of CAR therapy rapidly advances, novel methods to optimize this therapeutic modality are imperative. To this end, supported by research demonstrating superior antitumor function of naïve derived effector T cells compared to central memory derived effector T cells, I am investigating whether preferential modification of naïve T cells to express CARs will generate a T cell subpopulation with increased efficacy. Consolidating my clinical and research experiences within highly academic institutes allows me to synthesize my pursuit of scientific rigor and commitment to the field of oncology, with a mission to achieve productive research and translatable results.
-
Neil Schwartz, MD, PhD
Clinical Professor, Neurology & Neurological Sciences
Clinical Professor (By courtesy), NeurosurgeryCurrent Research and Scholarly InterestsMy clinical interests involve inpatient and outpatient care of patients with neurovascular diseases, mostly ischemic and hemorrhagic stroke. I have a particular interest in cervical artery dissection, non-atherosclerotic vasculopathies, and stroke in the young.
-
Christopher Thomas Scott, PhD
Sr Research Scholar, Pediatrics - Center for Biomedical Ethics
Current Research and Scholarly InterestsMy research focuses on the political, legal, ethical and economic impacts of stem cell research. Topics include: embryonic and adult stem cell research and clinical trials, stem cell banking, human-animal chimeras; cell and gamete donation; international perspectives of bioethics; global economic impacts; national and state regulatory policy, stem cell entrepreneurship, intellectual property and offshore stem cell transplants.
-
Jake Scott
Clinical Associate Professor, Medicine - Infectious Diseases
BioDr. Jake Scott is a board-certified infectious diseases specialist. He provides general infectious diseases care in the inpatient and outpatient settings and his special interests include COVID-19, coccidiomycosis, multidrug-resistant organisms, HIV, and HIV pre-exposure prophylaxis. He works with patients from diverse backgrounds to provide compassionate, high-quality care aligned with their needs.
Dr. Scott was born and raised in the Bay Area and was inspired to pursue a career in medicine after working as an HIV test counselor in San Francisco. He studied literature and creative writing in college and values the narrative aspect of medicine and the importance of drawing out the story behind the diagnosis.
One of Dr. Scott’s passions is teaching. He regularly works with Stanford residents and students and has lectured on various infectious disease-related topics, such as COVID-19, fever of unknown origin, and the dangers of antibiotic overuse, especially as it contributes to the rising threat of multidrug-resistant infections. He is also committed to expanding awareness of infectious diseases outside of the hospital and university through public presentations in the community and media interviews.
He is the medical director of the Antimicrobial Stewardship Program at Stanford Health Care – ValleyCare in Pleasanton and is a member of the Infection Control Committee and the Stanford Vaccine Clinical Advisory Committee.
In his spare time, Dr. Scott enjoys rock climbing, hiking, and spending time with his wife and two young children. -
Matthew P. Scott
Professor of Developmental Biology, Emeritus
Current Research and Scholarly InterestsOur research has been focused on the genetic regulation of animal development and its relation to birth defects, cancer, and neurodegeneration. We studied mechanisms and functions of Hedgehog (Hh) signaling, which controls cell fates and growth, in the context of normal development and brain cancer. We studied a neurodegenerative disease, Niemann-Pick C syndrome, that affects intracellular organelle movements and sterol homeostasis. Due to Dr. Scott's new job, the lab is no longer active.
-
Katharine Sears Edwards
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsPotential impact of brief behavioral interventions to improve adjustment, coping, medical adherence, and cardiovascular health among cardiac patients.
Psychosocial challenges of patients with spontaneous coronary artery dissection (SCAD).
Assessment and training in evidence-based psychological therapies. -
Vittorio Sebastiano
Associate Professor (Research) of Obstetrics and Gynecology (Reproductive and Stem Cell Biology)
Current Research and Scholarly InterestsThe thread of Ariadne that connects germ cells, preimplatation development and pluripotent stem cells is the focus of my research, with a specific interest in human development. My long-term goals are: 1. Understanding the biology of germ cells and and their ability to sustain early preimplantation development; 2. Understanding the mechanisms that regulate very early cell fate decisions in human embryos; 3. Understanding the biology of derivation and maintenance of Pluripotent Stem Cells
-
Talal Seddik
Clinical Associate Professor, Pediatrics - Infectious Diseases
Current Research and Scholarly InterestsTalal Seddik is a member of the Collaborative Antiviral Study Group. He is the key site investigator at the Stanford site for the following multicenter studies:
1) DMID 19-0026 Enterovirus Study
Neonatal Enterovirus and Human Parechovirus Viral Sepsis: Natural History and Predictors of Morbidity and Mortality
This study will be the first large, multi-state prospective assessment of the viral causes of neonatal sepsis conducted. The main reason for this research study is to get a better understanding of what causes neonatal viral sepsis and to assess the impact of the infection on the babies’ health. Viruses called enterovirus (EV) or human parechovirus (HPeV) are very common in the population and can cause neonatal viral sepsis. By gaining a better understanding of the condition, we hope this information can be used to guide diagnosis and treatment of babies with neonatal viral sepsis in the future.
This study is actively enrolling subjects
2) DMID 19-0005 Acute Flaccid Myelitis (AFM) Study
A Prospective Study of Acute Flaccid Myelitis (AFM) to Define Natural History, Risk Factors and Pathogenetic Mechanisms
Patients with suspected AFM (onset of flaccid limb weakness within the previous 30 days) are eligible to enroll in the study. Investigators will assess participants at four-time points within the first month of enrollment and will ask participants to return for additional follow up visits at 3 months, 7 months and 1 year. Neurologic improvements will be tracked over time, and samples will be collected and stored in a biorepository for use in future research studies. Household contacts, such as siblings, will be eligible to participate in the study as a control or comparison group.
This study is actively enrolling subjects. -
Rebecca Seekamp, MD
Clinical Assistant Professor, Medicine - Primary Care and Population Health
Current Research and Scholarly InterestsInterested in complementary/alternative medicine, international health, international adoption medicine and providing full spectrum health care.
